DiaMedica Inc. Announces Public Offering

DiaMedica Inc. ("DiaMedica" or the"Company") (TSX VENTURE:DMA), announced today
that it has entered into an engagement letter with Sora Group Wealth Advisors
Inc. ("Sora") and filed a preliminary short form prospectus (the "Prospectus")
in connection with the public offering (the "Offering") of units of the Company
(the "Units"). The Offering is expected to raise up to $3 million.


Each Unit will consist of one common share in the capital stock of the Company
(a "Common Share") and one common share purchase warrant (a "Warrant"). Each
Warrant will entitle the holder thereof to purchase one Common Share within two
years from the initial closing date of the Offering, subject to an acceleration
of the expiry date of such Warrants in certain circumstances as more
particularly described in the Prospectus.


The Offering is being placed on a best efforts basis by Sora. The price of the
Units and the exercise price of the Warrants will be determined by DiaMedica and
Sora in the context of the market.


The Company has granted to Sora, as agent, an option exercisable in whole or in
part at any time prior to the closing date of the Offering, to increase the
number of Units offered by up to 15%.


DiaMedica has applied to the TSX Venture Exchange (the "Exchange") to list the
Common Shares sold pursuant to the Offering and the Common Shares underlying the
Warrants. Listing is subject to DiaMedica satisfying all requirements of the
Exchange.


The total net proceeds from the Offering will be used to fund our ongoing
research and development programs, including preparation for clinical trials for
our lead products, as more particularly described in the Prospectus.


About DiaMedica

DiaMedica is a biopharmaceutical company that develops novel therapeutic
products designed to improve the lives of people with Type 1 diabetes, Type 2
diabetes and other large, medically unmet diseases. DiaMedica's lead product
candidate, DM-199, has been shown to protect and proliferate beta cells and
significantly improve glucose metabolism in preclinical models.


The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.